



Acadia Pharmaceuticals Inc. is providing this letter in response to your unsolicited request for medical information. It is for scientific exchange and individual educational purposes only, and should not be copied or distributed.

ACP-204 is an investigational agent, and its safety and efficacy have not been established and approved by the FDA. This letter is not intended to promote or recommend ACP-204 for any use. Acadia strives to provide current, accurate, and fair-balanced information in compliance with current industry information dissemination guidelines.

Remlifanserin (ACP-204) Clinical Development Program in Lewy Body Dementia Psychosis

This letter is provided in response to your specific request for information regarding the remlifanserin clinical development program in Lewy body dementia (LBD) psychosis. Remlifanserin is an investigational agent, and its safety and efficacy for the treatment of hallucinations and delusions associated with LBD psychosis have not been established and approved by the FDA.


Summary

- The efficacy and safety of remlifanserin (30 mg and 60 mg, once daily [QD]) is being investigated in adults with hallucinations and delusions associated with LBD psychosis in the Phase 2 [ILLUMERA](#) study (ACP-204-012).¹
 - The primary endpoint is the change from baseline in Scale for Assessment of Positive Symptoms–LBD psychosis (SAPS-LBDP) total score at Week 6.¹
- Participants completing ILLUMERA will be eligible to enroll in an open-label extension (OLE) study, [ACP-204-013](#), that will evaluate the safety and tolerability of long-term remlifanserin treatment in participants with LBD psychosis for up to 52 weeks.²

Clinical Studies in LBD Psychosis

The efficacy and safety of remlifanserin is being investigated in participants with hallucinations and delusions associated with LBD psychosis in a 6-week Phase 2 study and a long-term OLE study (**Figure 1**).^{1,2}

Figure 1. Remlifanserin Studies in LBD Psychosis^{1,2}




Abbreviations: LBD=Lewy body dementia; PO=orally; QD=once daily.

ILLUMERA (ACP-204-012)

ILLUMERA is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study in participants with LBD psychosis (i.e. either PD dementia psychosis or dementia with Lewy bodies [DLB] psychosis). An estimated 180 participants will be randomized to one of 3 parallel arms, i.e., remlifanserin at one of 2 dose levels (30 or 60 mg) or placebo, for a double-blind treatment period of up to 6 weeks (**Figure 2**). Randomization will be stratified by diagnosis of PD dementia psychosis (50% cap) or DLB psychosis. The primary endpoint measure, SAPS-

LBDP total score, includes the same 9 of the 20 hallucinations and delusions items in the Scale for Assessment of Positive Symptoms Hallucinations and Delusions domains (SAPS-H+D) as the PD-adapted Scale for Assessment of Positive Symptoms (SAPS-PD). The key secondary endpoint measure, the Clinical Global Impression-Severity (CGI-S)-LBDP scale, is the CGI-S scale applied in the LBD psychosis context, in which hallucinations and delusions are the symptoms of interest.^{1,3}

Figure 2. ILLUMERA Study Design^{1,4}



*Randomization stratified by diagnosis of PD dementia psychosis (50% cap) or DLB psychosis (no cap).

Abbreviations: BPST=brief psychosocial therapy; CGI-S-LBDP=Clinical Global Impression-Severity in the LBD psychosis context; DLB=dementia with Lewy bodies; LBD=Lewy body dementia; PD=Parkinson's disease; PO=orally; QD=once daily; SAPS-LBDP=Scale for Assessment of Positive Symptoms in the LBD psychosis context.

There will be a screening period of up to 30 days,¹ during which the designated study partner/caregiver will be given instructions on engaging in a structured psychosocial interaction with the participant (brief psychosocial therapy).⁴ After completing the 6-week double-blind treatment period, participants who do not enroll in the OLE study will undergo two safety follow-ups (one at 7 days and one at 30 days). For participants who discontinue prematurely from the study, an additional mortality follow-up will be conducted 30 days after the participant's intended day of last dose of study drug.¹ Selected inclusion and exclusion criteria for ILLUMERA are shown in **Table 1**.

Table 1. ILLUMERA Selected Inclusion and Exclusion Criteria^{1,3}

Selected inclusion criteria	
•	Male or female participants, ≥55 and <85 years of age, living in the community or in an institutionalized setting
•	Meets either the clinical criteria for PD with dementia (as defined by the MDS Task Force) or revised clinical criteria for probable DLB (Fourth Consensus report of the DLB Consortium)
•	Meets the revised criteria for psychosis in major or mild neurocognitive disorder established by the IPA
•	MMSE score ≥6 and ≤28 at screening and baseline
•	Had psychotic symptoms for ≥2 months prior to screening visit
•	Has the following scores at screening and baseline:
○	SAPS Hallucinations or Delusions global item (H7 or D13) score ≥3 AND a score ≥3 on at least one other non-global item using the SAPS-LBDP
○	CGI-S-LBDP score ≥4
•	Has a prior MRI or CT scan of the brain that is consistent with the diagnosis of LBD
•	Must be on a stable dose of cholinesterase inhibitor, memantine, and/or dopaminergic medications for ≥12 weeks prior to baseline or discontinued ≥2 weeks prior to baseline
•	Antipsychotics must be discontinued ≥3 days prior to baseline
Selected exclusion criteria	
•	In hospice and receiving end-of-life palliative care, or has become bedridden

- Requires ongoing skilled nursing or medical care of IV lines or surgical openings to the wind-pipe or bladder
- Has psychotic symptoms that are primarily attributable to delirium, substance abuse, or a medical or psychiatric condition other than dementia
- Major depressive episode meeting DSM-5 criteria within 3 months of screening
- Actively suicidal at screening or baseline*
- Known personal or family history or symptoms of long QT syndrome
- Has a history of nonresponse to pimavanserin treatment

*Includes an answer of “yes” to C-SSRS questions 4 or 5 (current or over the past 6 months), has attempted suicide in the 2 years prior to screening, or has a GCAS score of 3 or 4 within 3 months of screening.


Abbreviations: CGI-S-LBDP=Clinical Global Impression-Severity in the LBDP context; C-SSRS, Columbia-Suicide Severity Rating Scale; CT=computed tomography; DLB=dementia with Lewy bodies; DSM-5=Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; GCAS=Global Clinician Assessment of Suicidality; IPA=International Psychogeriatrics Association; IV=intravenous; LBD=Lewy body dementia; LBDP=Lewy body dementia psychosis; MDS=Movement Disorder Society; MMSE=Mini-Mental State Examination; MRI=magnetic resonance imaging; PD=Parkinson’s disease; SAPS=Scale for Assessment of Positive Symptoms; SAPS-LBDP=LBDP-adapted Scale for the Assessment of Positive Symptoms.

Benzodiazepines (lorazepam up to 1 mg/d or equivalent) are allowed as rescue medication as needed for severe neuropsychiatric or behavioral disturbances.¹

ACP-204-013

This is a 52-week, OLE study enrolling participants who complete the Phase 2 ILLUMERA study (**Figure 3**).² The primary objective is to evaluate the safety and tolerability of long-term remlifanserin treatment in participants with LBD psychosis.⁵

Figure 3. Study Design for ACP-204-013²



*After the initial remlifanserin dose of 30 mg on the day after the baseline visit, the remlifanserin dose may be adjusted first up for suboptimal efficacy or later down for tolerability concerns, once or more than once, to 30 mg or 60 mg administered QD. Abbreviations: LBD=Lewy body dementia; PO=orally; QD=once daily; TEAE=treatment-emergent adverse event.

All eligible rollover participants from ILLUMERA will begin remlifanserin 30 mg QD dosing on the day after the end-of-treatment visit for the antecedent study, which serves also as the baseline visit for this study, ACP-204-013.^{2,5} After the initial remlifanserin dose of 30 mg on the day after the baseline visit, the remlifanserin dose is flexible, and may be adjusted first up for suboptimal efficacy or later down for tolerability concerns, once or more than once, to 30 mg or 60 mg administered QD.²

References

1. Nunez R, et al. Design of the Phase 2, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of ACP-204, a Novel 5-HT_{2A} Selective Inverse Agonist/Antagonist, in Adults With Lewy Body Dementia Psychosis. Poster

presented at the International Congress of Parkinson's Disease and Movement Disorders; October 5-9, 2025.

2. National Institutes of Health. Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis. [\[Link\]](#).
3. National Institutes of Health. Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP. [\[Link\]](#).
4. Acadia Pharmaceuticals Inc. Data on File. ACP-204-012 Protocol. 2025.
5. Acadia Pharmaceuticals Inc. Data on File. ACP-204-013 Protocol. 2025.